First imported coccidioidomycosis in Turkey: a potential health risk for laboratory workers outside endemic areas

Kantarcioglu, S.A.; Sandoval-Denis, M.; Aygun, G.; Kiraz, N.; Akman, C.; Apaydin, H.; Karaman, E.; Guarro, J.; de Hoog, G.S.; Gurelg, M.S.

DOI
10.1016/j.mmcr.2014.01.002

Publication date
2014

Document Version
Final published version

Published in
Medical Mycology Case Reports

Citation for published version (APA):

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
First imported coccidioidomycosis in Turkey: A potential health risk for laboratory workers outside endemic areas

A. Serda Kantarcioglu a,*, M. Sandoval-Denis b, Gokhan Aygun a, Nuri Kiraz a, Canan Akman c, Hulya Apaydin d, Emin Karaman e, Josep Guarro b, G. Sybren de Hoog f, M.S. Gurel g

a Cerrahpasa Medical Faculty, Department of Medical Microbiology, Deep Mycosis Laboratory, Istanbul University, Istanbul 34098, Turkey
b Unitat de Microbiologia, Facultat de Medicina i Ciencies de la Salut, ISPV, Universitat Rovira i Virgili, 43201 Reus, Spain
c Cerrahpasa Medical Faculty, Department of Radiology, Istanbul University, Istanbul 34098, Turkey
d Cerrahpasa Medical Faculty, Department of Neurology, Istanbul University, Istanbul 34098, Turkey
e Cerrahpasa Medical Faculty, Department of Otorhinolaryngology, Istanbul University, Istanbul 34098, Turkey
f CBS-KNAW Fungal Biodiversity Centre, Utrecht, The Netherlands
g Department of Dermatology, Samatya Training and Research Hospital, Istanbul 34098, Turkey

A R T I C L E   I N F O
Article history:
Received 3 November 2013
Received in revised form 19 December 2013
Accepted 10 January 2014

Keywords:
Coccidioidomycosis
Coccidioides
Non-endemic countries
Laboratory safety

A B S T R A C T
Coccidioidomycosis caused by Coccidioides immitis or Coccidioides posadaii is endemic in arid climate zones in America, travel-related cases have been reported. We report the first documented case of coccidioidomycosis in Turkey, overviewing reported cases in Europe and underlying difficulties of differential diagnosis outside endemic regions. The patient was an otherwise healthy 41-year-old man who travelled endemic areas. Laboratory diagnosis was based on direct microscopy of two subsequent subcutaneous biopsy specimens and culture and confirmed molecularly. Laboratory personnel should become aware that Biosafety Level-3 organisms may become more frequent and widespread.


1. Introduction

Coccidioidomycosis is an endemic disease of arid and semi-arid regions of northern and southern America caused by Coccidioides posadaii and Coccidioides immitis, which can only be separated by DNA sequencing. Travellers to endemic areas are at risk of developing coccidioidomycoses through inhalation of airborne conidia. A history of travel to endemic areas as well as a high index of suspicion is imperative for timely and accurate diagnosis [1]. In order to differentiate this infection from other systemic mycoses, diagnostic spherules should be observed in clinical samples, and/or typical barrel shaped arthroconidia in culture. The present case is the first report of proven, imported coccidioidomycosis in Turkey. Unfamiliarity with the disease might present a severe biohazard to laboratory personnel.

2. Case

On June 2011, a 41-year-old, otherwise healthy, Turkish man travelled to Texas for 2 months where he spent his spare time in walking through the forests, and then took 1 month trip by car to Grand Canyon, Las Vegas and San Francisco during which he fasted in accordance with Ramadan, but felt unusually weak and lost weight. On his 80th day in the USA, he felt very ill near Niagara Falls and laid down on the grass, suffered from chest pain and severe sweating. Ten days later, he was admitted to an hospital in Texas with coughing, fever, vomiting and loss of appetite (day 0). He was diagnosed with pneumonia and given 400 mg/day moxifloxacin. The next day he returned to Batman, Turkey and attended University Hospital with nausea, vomiting, weakness, sweating, productive coughing and fever (day +1). Serologic assays for IgM levels of CMV, Herpes type II, Rubella, Parvovirus B19, and EBV EBNA were all negative. CRP was 30.7 mg/L and increased to 42.5 mg/L (day +4). Sputum, throat, urine cultures and haemoculture as well as stains for acid-fast bacteria and mycobacterial cultures were also negative while moxifloxacin was continued. Chest X-rays were normal but chest CT scan revealed a 18 mm nodule on the left upper lobe with suspected histoplasmosis. Bronchoscopy showed white mucosal nodularity and a biopsy was performed. Fungal cultures of the biopsy specimen were

* Corresponding author.
negative. A blood sample gave negative result for Histoplasma DNA identification by PCR. Abdominal ultrasound and a cranial CT scan were normal. Due to persistent fever up to 40 °C and night sweat, patient was switched to imipenem and clarithromycin. He refused pulmonary biopsy and left hospital (day +11).

Following the development of a cutaneous lesion of about 1 cm diameter on his neck (day +38), he attended University Hospital in Ankara and was hospitalised. CRP level was 15.8 mg/L and increased to 22.5 mg/L (day +42). Routine clinical laboratory data were unremarkable. Cytology and stains for acid-fast bacteria, as well as fungal and mycobacterial microscopy and cultures of two subsequent bronchoalveolar lavage (BAL) samples and a lymph node biopsy specimen were all negative. For his neck lesion, amoxicillin-clavulanic acid, 1000 mg, t.i.d. and a topical fusidic acid cream were started and then he was discharged (day +46).

He attended Batman State hospital with severe chest pain, lack of appetite, the persistent lesion on the neck and an additional small papule in the left palm (day +47). An abdominal CT scan revealed ascites, and the cytology of aspirated peritoneal fluid showed numerous lymphocytes, neutrophils, eosinophils and histiocytes.

He was admitted to another hospital and a chest CT scan revealed a nodule of about 18 mm on the left upper lobe and oedema (day +54). Pathological examination of a punch biopsy of his neck lesion revealed pseudoepitheliomatous hyperplasia-like verrucose proliferation and neutrophils in the epidermis. A dense infiltrate of neutrophils, lymphocytes, plasma cells, histiocytes and eosinophils invading epithelia were present in the dermis. Langerhans-like multi-nuclear giant cells and granuloma formations were also observed. PAS-positive, round, thick-walled fungal elements were observed in the cytoplasm of the giant cells in neutrophilic abscesses. North American blastomycosis was suspected. Stains for acid-fast bacteria and mycobacterial cultures were negative. Histopathological preparations sent for consultation were reported as being fungal dermatitis. Itraconazole (ITZ) 100 mg b.i.d. was prescribed for 6 months.

When he was admitted to a university hospital in Ankara (day +164), CRP level was 1.74 mg/L. A chest CT scan revealed additional lymph nodes with an infectious appearance in the left lung. Parenchymal lesions were smaller than they were on the day +4. No ascites was detected on abdominal CT scan. He was free of pain. ITZ treatment was continued. A chest CT scan made in Batman (day +308) showed micronodules in the left lung and left hilar lymphadenopathy of a “tree-in-bud” appearance with some regression when compared with the CT scans of day +2. His palm lesion was healed but lung lesions were sustained after having been treated with ITZ 200 mg/day for 6 months. On follow-up visit (day +363), because of his persisted neck lesion despite ITZ treatment, the patient was transferred to a Research Hospital in Istanbul for further evaluation for suspected blastomycosis and its treatment with amphotericin B (AMB).

When he admitted to the dermatology department (day +368), he was concious, cooperative and oriented with normal physical examination. He had an erythematous, slightly elevated atrophic lesion on his neck of about 4.3 cm and brightly coloured peripheric minor papules. Serology for HBsAg, Anti HBs, Anti HCV and Anti-HIV were all negative. Neck ultrasonography revealed several lymph nodes having a reactive appearance, smaller than 12 mm in diameter. Abdominal magnetic resonance imaging (MRI), cranial CT scans and a whole body bone scintigram were normal (day +373). Pulmonary radiological scans were thought compatible with blastomycosis.

Two subsequent punch biopsies of 5 mm were carried out (days +368 and +379) and sent to Cerrahpasa Medical Faculty (CMF), Deep Mycoses Laboratory (DML), with clinical suspicion of North American blastomycosis and the patient was discharged at his own request. Previous histopathological sections were requested from the laboratory for mycological re-examination. Coccidioides sp. was identified by microscopy and two subsequent biopsy samples were cultured. Treatment was continued with ITZ 200 mg/day for 3 months.

When the patient was seen on day +465, his neck lesion was healed and his physical examination and routine clinical laboratory data were unremarkable. On the chest CT scan parenchymal nillary lesions were resolved, lesions defined on the left lung and mediastinal windows showed no significant differences with those of the previous years, but there was a significant reduction of the diameter of the left axillary and mediastinal lymph nodes. Nodular consolidation documented on the left lung altered to granuloma-like configuration (Fig. 1). A nasal endoscopy was carried out. A previous sinoorbital MRI was reviewed but revealed no abnormality except
right concha hypertrophy and deviation of nasal septum. Neurological examination was normal. Previous MRIs of the brain were re-examined. A T2-weighted MRI of the brain showed a few small gliotic foci on the basal surface of the frontal lobe as well as tubinate hypertrophy of the nasal mucosa that blocked the nasal passage. A lumbar puncture revealed normal opening pressure with normal biochemistry. A cerebrospinal fluid (CSF) sample was sent to the Deep Mycoses Laboratory. CSF direct microscopy and cultures of the CSF samples were negative. Based on radioscopic data, antifungal treatment was continued and a 3-month follow-up appointment scheduled.

When seen on day +564, physical examination and routine laboratory data were normal. Antifungal therapy was stopped. He is now free of symptoms. Authors speculate that the presence of turbinate hypertrophy of the nasal mucosa facilitated the incubation of the pathogen.

2.1. Materials and methods

Two subsequent biopsy specimens from neck nodules were submitted to CFM, DML for mycological evaluation (days +368 and +379), with a clinical suspicion of North American blastomycosis. Direct microscopical examination was carried out using Gram, Ehrlich Ziehl Nielsen, Giemsa, and methylene blue stained slide preparations of the imprinted tissue samples. Specimens were inoculated by embedding onto Sabouraud dextrose agar (SDA), chocolate agar with sheep blood (5%) plates as primary culture media and incubated at 30°C and 37°C. Microscopic morphology of the isolate was examined by staining with lactophenol cotton blue. PAS stained histopathological preparations from day +54 were also requested and examined for microorganisms. Phenotypical identification was made using classical mycological techniques.

The isolate was identified by sequencing of the internal transcribed spacers (ITS) 1 and 2, and 5.8S domains of rDNA. They were compared with the sequences of type and reference strains deposited in GenBank.

In vitro susceptibility of the isolate against AMB, ITZ, fluconazole (FLZ), voriconazole (VRZ) and posaconazole (PSZ) was examined using MIC Test Strip (Liofilchem s.r.l., Italy). Tests were carried out according to the manufacturer’s instructions.

2.2. Results

Direct microscopical examination of Giemsa stained imprinted tissue slides of biopsy materials revealed the presence of a few, thick-walled, round fungal cells, some with a granular protoplasm (Fig. 2), small chains of oval to round cells and a few sporangium-like, large, thick walled, round, dense or empty cells of between 20 and 40 μm in size (Fig. 3), with double-contoured wall. Histopathological sections of the tissue biopsy carried out on day +54 were sent for mycological re-examination and the organism appeared in tissue in double-encapsulated, empty spherical form.

After 4–5 days incubation, cultures on SDA at 30°C and 37°C initially grew glabrous colonies just around the tissue biopsy specimens. Fungal morphology seen directly in patient material and glabrous colonial characteristics of the early culture raised the possibility of the presence of a *Prototheca* sp, compatible with his rest near a waterfall. However, after 2–3 weeks of incubation the colonies were white, floccose, with a tan reverse. The same fungus was isolated as pure culture from all the tissue samples. Microscopic examination of lactophenol cotton blue stained slide preparations made at the early mould phase revealed smooth, hyaline, septate, sterile hyphal structures with some spirals similar to those of dermatophytes. When colonies had matured, for about 2–3 weeks (Fig. 4), barrel-shaped arthroconidia were observed. Fungal morphology allowed the tentative identification of the fungus as *Coccidioides* sp. Subcultures were submitted to JG at Reus for molecular confirmation and the strain was identified as *C. immitis* by sequencing the rDNA ITS region showing a 99% sequence similarity with the reference strains CBS 113852, CBS 113856 and CBS 113857 (accession numbers EF186788, EF186789 and EF186790, respectively). The sequence generated was deposited in GenBank under the accession number HG380500.
isolate is stored in the collection of University of the Centraal bureau voor Schimmelcultures, Utrecht, The Netherlands, at CBS 136242 (FMR 12608).

MICs (μg/ml) were 32 for AMB, > 256 for FLZ, > 32 for ITZ, 0.64 for VRZ, 0.047 for PSZ.

2.3. Exposure by laboratory staff and environmental controls

Regarding the results of direct microscopical examination of tissue preparations stained by PAS and Giemsa methods and early glabrous colony morphology, prothothecosis, chlorellosis, cocci-diodomycosis or skin dermatophytosis were all initially suspected. Culture slides were prepared twice, once at the early mould growth phase and again at maturity. Early preparations revealed only thin, hyaline, septate hyphae without conidia, resembling dermatophyte hyphae but mature colonies revealed the presence of typical barrel-shaped arthroconidia. All patient’s cultures were immediately destroyed by autoclaving them together with biological waste. Environmental controls were carried out periodically in both the mycology laboratory and inside the incubators. Petri dishes containing SDA were opened for 3 h and then incubated at 30°C and 37°C. The same fungus grew in cultures, which were autoclaved immediately. All surfaces in the laboratory were disinfected using sodiohyphochlorite (10%) and the cleaning staff wore N95 respirators, disposable protective laboratory coatings, gloves and hair covers. Air was decontaminated with pulverising hydrogen peroxide (15 ml/m³), allowing overnight contact. The DML was kept closed, signs were posted to alert personnel that this may be a contaminated area that should not be entered and work was transferred to another room. The Infectious Disease Committee of CMF was officially informed immediately. Environmental controls and decontamination using hydrogen peroxide were carried out four more times. Air sampling and cultures are still currently being continued as a precaution despite culture results having been negative on the third test. Serum samples of personnel were taken and stored. Nasopharyngeal and sputum samples of laboratory staff were cultured. Antifungal prophylaxis with ITZ was given at a therapeutic dose to laboratory workers for 3 months and sinonasal staff were cultured. Antifungal prophylaxis and stored. Nasopharyngeal and sputum samples of laboratory workers were taken at the end of the prophylaxis, which showed no abnormalities.

3. Discussion

Although travel history is important in diagnosing endemic mycosis particularly in non endemic countries, it is not always easy. In the present case, the patient was first diagnosed as North American blastomycosis in several separate hospitals based on his travel story and clinical findings dispite negative culture, during nearly 1 year course.

Diagnosis of coccidioidomycosis is usually determined based on the presence of endospores however microscopical findings are not always typical. Environmental algae Prototheca and Chlorella spp. can be isolated from grass, soil and water and malnutrition is listed among risk factors of algae infection as was in this patient. The two subsequent biopsy specimens revealed randomly distributed atypical thick-walled large yeast-like cells that were not indicative of either Coccidioides sp. or an algae infection. Multinucleated endosporulating sporangium-like, small, immature spherules seen in Giemsa and PAS stained tissue preparations, double-encapsulated, empty spherical form seen in histopathological sections and initially glabrous colony morphology on SDA lead us to suspect both algal infection and cocci-diodomycosis. Misleading and unusual immature forms of C. immitis have previously been reported in vivo [2–5]. Undiagnostic, thin, hyaline hyphae seen in preparations of this glabrous colony pointed to a possible dermatophyte isolation, albeit from two separate biopsy specimens. Although single-celled, barrel-shaped arthroconidia were expected to occur in 4–7 days on SDA at 25°C, the late maturation of the isolates might probably be due to the partial inhibition of the patient’s long-term antifungal treatment before biopsy specimens were obtained and submitted to DML.

A positive serological test may have diagnostic value for acute coccidioidomycosis in patients from nonendemic countries, particularly in relation with a travel history, but negative tests should not be used to rule out the disease, and serological tests for C. immitis are uncommon in Europe and Turkey. Karasu and Sirman [6] carried out serological tests using coccidioidin antigen in 1953. They applied both histoplasmin and coccidioidin to 66 patients with pulmonary lesions and 11 of them were positive for both antigens and two of them positive for coccidioidin.

Today’s changes in travelling behaviour may increasingly cause people to encounter infections with organisms that are uncommon in their own countries. Because of the low incidence of coccidioidomycosis on Europe, diagnosis of the disease is not well known in practice. We found 19 cases of coccidioidomycosis imported into Europe as outlined in Table 1 [7–25]. In the data given by the European Confederation of Medical Mycology (ECMM) Working Group of the Survey of Coccidioidomycosis in Europe, 36 cases were reported from nine countries but limited or no data were provided (http://www.ecmm.eu/node/193). The first report in Turkey [26] found spherule-like forms in skin biopsy specimens of facial erythematous papulo-pustular lesions presented by a 53-year-old woman gardener. Arthroconidia were seen in cultures of skin biopsy and blood. The strain was inoculated to mice and spherules were observed in visceral organs, although the isolate was not submitted to a reference centre for confirmation. Austen et al. [27] reported a patient from The Netherlands who travelled to California in 2008. Two weeks after her visit, she travelled to Turkey, where she was admitted to an intensive care unit with severe “community-acquired pneumonia”, but no pathogen was identified. The authors presume that this was probably a primary infection by coccidioidomycosis. We report the first coccidioidomycosis case, proven by culturing, in Turkey.

Approximately 40% of infected people are asymptomatic or develop flu-like symptoms. In rare instances, individuals develop severe lung disease (e.g., cavitary pneumonia) and in < 1% of infected people the fungus disseminates to the central nervous system, joints, bones and skin [1]. Although our patient was an otherwise healthy, relatively young, returned home soon with severe symptoms and developed disseminated infection with a skin lesion on his neck and one in palm.

The literature on antifungal susceptibility testing of Coccidioides spp. is rather limited. In review of previous susceptibility studies of Coccidioides spp. MIC ranges (μg/ml) were reported as 0.06–2 for AMB, 0.03–1.0 for ITZ, 2.0–64.0 for FLZ, < 0.06–1 for VRZ and PSZ [28]. Although the fungus appeared in vitro to be highly susceptible to most antifungal agents, the treatments for chronic and disseminated coccidioidomycosis can be prolonged and often complicated and only 50–60% of patients are responsive to treatment with ITZ and FLZ [29]. In this case the fungus was isolated from biopsy samples obtained on day +310 of ITZ treatment and showed high MIC values both for FLZ (> 256) and ITZ (> 32). Since no defined susceptibility breakpoints exist for both FLZ and ITZ activity against Coccidioides spp., and comparable MIC values of the wild type isolate were not available, and the patient’s response to ITZ gradually decreased, facing such a high MIC value may suggest possible acquired resistance to both azoles occurred during long term therapy. Voriconazole and PSZ which were apparently more
active azoles *in vitro* were reported as options for salvage treatment of refractory coccidioidomycosis in patients who were unresponsive to the first line antifungal agents [30,31]. When seen on day + 564, the patient’s physical examination and routine laboratory data were normal. Antifungal therapy was stopped. Actually, the patient is free of symptoms.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Patient characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kantarcioglu</td>
<td>41/M/Turkish Otherwise healthy Texas Pulmonary nodules/skin Biopsy ITZ (200 mg/day) Asymptomatic</td>
</tr>
<tr>
<td>Austen et al. [27]</td>
<td>77/F/NL Otherwise healthy California (2008) Total knee arthroplasty Aspirate of the knee FLZ (400 mg/day, life long)</td>
</tr>
<tr>
<td>Gobbi et al. [8]</td>
<td>28/M/Italian Otherwise healthy Arizona Pulmonary nodules BAL/Gram staining; serum/anti-coccidioidin antibodies ITZ (200 mg b.i.d., 6 months)</td>
</tr>
<tr>
<td>Lacassagne et al. [10]</td>
<td>57/F/French Otherwise healthy Arizona A solitary pulmonary nodule Surgical resection material NM Asymptomatic and well (1 year later)</td>
</tr>
<tr>
<td>Brugiere [11]</td>
<td>58/M/French Lung transplant recipient NM NM NM</td>
</tr>
<tr>
<td>Indhirajanti et al. [12]</td>
<td>35/M/NL Otherwise healthy California NM BAL/culture and serology ITZ (Continued) Gradually improved</td>
</tr>
<tr>
<td>Buijze et al. [13]</td>
<td>58/M/Asian Otherwise healthy California Pulmonary abscess Lymph node biopsy FLZ (400 mg/day), lack of therapeutic response, changed into KTZ (400 mg once daily) Stabilized</td>
</tr>
<tr>
<td>Goeggber et al. [14]</td>
<td>34/M/Belgium Otherwise healthy Pulmonary nodule, lymph node NM Tissue from wedge resection No specific therapy was initiated Good general condition NM</td>
</tr>
<tr>
<td>Hombach et al. [15]</td>
<td>61/M/Swiss Otherwise healthy Arizona Pulmonary abscess with a cavity BAL/culture NM NM</td>
</tr>
<tr>
<td>Chandesris et al. [16]</td>
<td>63/F/Vietnamese living in France Otherwise healthy Los Angeles Pulmonary abscess BAL/culture ITZ (600 mg/day, 2 months) Lost to follow up</td>
</tr>
<tr>
<td>Pistone et al. [17]</td>
<td>46/M/Colombian immigrant HIV+, mucocutaneous Kaposi’s sarcoma, candidiasis, histoplasmosis, Pulmonary abscess Archeologist/Mexico and Caribbean Pulmonary abscess BAL/culture NM</td>
</tr>
<tr>
<td>Petrini et al. [18]</td>
<td>65/F/Sweden Otherwise healthy Arizona (8 months ago) Mexico Pulmonary nodules Probable lung localization Tissue/Grocotte-Gomori silver stain serology NM NM</td>
</tr>
<tr>
<td>Holemans et al. [22]</td>
<td>47/F/Swiss Otherwise healthy Arizona (3 years ago) NM Pulmonary abscess Biopsy culture, serology No antifungal therapy was given KTZ (400 mg/day, 4 months) Returned to US? symptomless</td>
</tr>
<tr>
<td>Fohlman et al. [19]</td>
<td>68/M/Swedish citizen 61/M/US citizen Otherwise healthy Arizona (2 years ago) Pulmonary abscess Multiple pulmonary abscesses Culture, serology No antifungal therapy was given KTZ (400 mg/day, 4 months) Returned to US?</td>
</tr>
<tr>
<td>Zalatnai et al. [20]</td>
<td>39/M/Spanish HIV+, iv drug user Arizona, Nevada, California (12 years ago) Several enlarged lymph nodes in the left cervical and supraclavicular regions, radiographs of the chest were normal Microscopy and culture of cervical lymph node biopsy FLZ (400 mg, twice daily for 1 month, reduced to 400 mg/d for 4 months, 200 mg/day as secondary prophylaxis) Felt well (9 months later)</td>
</tr>
<tr>
<td>Hernandez et al. [21]</td>
<td>43/M/Sweden 25/M/USA Immunocompetent Black, soldier No travel history NM Adrenal Chest wall abscess NM Microscopy of abscess drainage AMB Felt well (9 months later)</td>
</tr>
<tr>
<td>Papadopoulos et al. [24]</td>
<td>43/M/Sweden 25/M/USA Immunocompetent Black, soldier No travel history NM Adrenal Chest wall abscess NM Microscopy of abscess drainage AMB Felt well (9 months later)</td>
</tr>
<tr>
<td>Libow et al. [23]</td>
<td>25/M/USA NM NM Adrenal Chest wall abscess Pulmonary Microscopy of abscess drainage AMB</td>
</tr>
<tr>
<td>Alanko et al. [25]</td>
<td>–/–/Finland Pregnant Arizona Pulmonary cavitation Culture of sputum and resected specimen Cavity resection, abortion, pre- and post-operative AMB Completely recovered</td>
</tr>
</tbody>
</table>

Abbreviations: AMB—amphotericin B; FLZ—fluconazole; ITZ—itraconazole; KTZ—ketoconazole; P—pulmonary involvement; NM—not mentioned.
All laboratory staff had to have an antifungal prophylaxis for 3 months against the risk of presence of mature disarticulated conidia in the air, although the benefits of such a prophylactic approach have not been proven. Early treatment of experimental coccidioidal infection in animal models clearly facilitates a favourable outcome [1,32].

Laboratory-associated coccidioidomycosis is a documented hazard of working with sporulating cultures of *Coccidioides* spp. [33–35]. Attack rates for laboratory exposure is higher than for ambient exposure when large numbers of conidia are inhaled [34]. Risk of respiratory infection from exposure to infected tissue or aerosols of infected secretions is low. Therefore, Biosafety Level 3 practices, containment equipment, and facilities were recommended for manipulating sporulating cultures of *Coccidioides* to avoid inhalation of infectious arthroconidia from cultures of the mould form [35].

In conclusion, with increase in international travels, coccidioidomycosis is now emerging as an important infection outside its previously known endemic areas. In non-endemic countries, in spite of the patient’s prior travel history, coccidioidomycosis may not be easy to diagnose if there has been previous empirical antifungal treatment and/or atypical strain morphology. Laboratory personnel may be at risk of exposure to fungal cells while working with unexpected fungi during incubation and identification. Furthermore, the lack of appropriate Biosafety Level 3 conditions in laboratories in European countries is a significant risk factor for exposure to *Coccidioides*.

**Conflict of interest**

There are none.

**References**


[27] Ramani R, Chaturverdi V. Antifungal susceptibility profiles of *Coccidioides immitis* and *Coccidioides posadasii* from endemic and non-endemic areas. Mycopathologia 2007;163:315–9.


[34] Biosafety in Microbiological and Biomedical Laboratories. 5th Ed. US Washington: Department of Health and Human Services Public Health Service Center for Disease Control and Prevention and National Institute of Health; 2009. p. 171–2.